Skip to main content
Bioera logo

Bioera — Investor Relations & Filings

Ticker · BIE ISIN · IT0005516130 LEI · 815600CE609AFE44D992 XMIL Manufacturing
Open in API
Filings indexed 558 across all filing types
Latest filing 2023-03-16 Share Issue/Capital Cha…
Country IT Italy
Listing XMIL BIE

About Bioera

https://bioera.it/en/

Bioera S.p.A. is a company specializing in the production and distribution of natural and organic products. Its core business involves the development and marketing of a diverse portfolio that includes organic food, traditional food products, natural cosmetics, herbal remedies, and food supplements. The company focuses on providing consumers with products derived from natural sources, catering to the health and wellness market.

Recent filings

Filing Released Lang Actions
BIOERA SPA -Conclusione asta inoptati
Share Issue/Capital Change Classification · 1% confidence The document is an official communication from BIOERA S.p.A. titled 'AUMENTO DI CAPITALE: CONCLUSA L'ASTA DEI DIRITTI DI OPZIONE NON ESERCITATI' (Capital Increase: Auction of Unexercised Option Rights Concluded). It details the results of an auction for unexercised rights related to a capital increase, specifying the number of rights sold, the resulting new shares, and the subscription price. This content directly relates to fundraising, financing activities, and changes in the company's capital structure. Therefore, it fits the definition of 'Capital/Financing Update' (CAP). Although it mentions a prospectus will be published later, the core subject is the completion of a financing step (the auction), making CAP more specific than RPA or RNS.
2023-03-16 Italian
BIOERA SPA - Esito offerta in opzione
Capital/Financing Update Classification · 1% confidence The document is a press release (COMUNICATO STAMPA) from BIOERA S.p.A. dated March 10, 2023. The subject (Oggetto) is 'Esito offerta in opzione' (Result of the rights offering). The text details the conclusion of the subscription period for a capital increase via a rights offering, the amount subscribed, and the subsequent offering of unsubscribed rights ('Diritti Inoptati') on the stock exchange (Asta dell'Inoptato). This clearly relates to a corporate action involving the issuance of new shares and changes to the capital structure. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an interim report (IR), or just a simple dividend notice (DIV). Since it is a detailed announcement about the results of a financing activity, CAP is the most appropriate classification.
2023-03-10 Italian
BIOERA SPA - Approvata pubblicazione supplemento informativo
Capital/Financing Update Classification · 1% confidence The document is a press release from BIOERA S.p.A. announcing that CONSOB (the Italian securities regulator) has approved the publication of an 'Informativo Supplemento' (Information Supplement) to a previously filed Prospectus. This supplement relates to capital increases (Aumenti di Capitale) and the admission of new shares to trading, specifically modifying the terms and timeline of an ongoing rights offering (Offerta in Opzione). The core subject is the publication/approval of documentation related to capital structure changes and financing activities (capital increases). This strongly aligns with the 'Capital/Financing Update' (CAP) definition. Although it mentions the publication of a supplement, the document itself is the announcement detailing the financing event and the regulatory approval, not just a generic announcement of a report release (RPA/RNS). The content is substantive regarding capital changes.
2023-03-08 Italian
BIOERA SPA - Supplemento al prospetto informativo 08/03/2023
Capital/Financing Update Classification · 1% confidence The document is titled "SUPPLEMENTO AL PROSPETTO INFORMATIVO" (Supplement to the Prospectus) and explicitly states it is a supplement to a previously filed prospectus ('Prospetto Informativo') concerning a capital increase ('Aumento di Capitale'). It details updates based on subsequent events, specifically concerning an associated company (Ki Group Holding S.p.A.) and its financial distress, which impacts Bioera's financial outlook and risks. A prospectus supplement is a document filed to update or amend the information in an existing registration statement or prospectus, typically related to an offering of securities. This aligns closely with documents related to capital raising or offering disclosures. Since the core document is an update to a Prospectus related to a capital increase (a financing activity), the most appropriate category is 'Capital/Financing Update' (CAP). While it is a regulatory filing, CAP is more specific than the general 'RNS' fallback, as it directly concerns the terms of a capital operation.
2023-03-08 Italian
BIOERA SPA Supplemento al prospetto informativo pubblicato lo scorso 13 febbraio 2023. Prorogato il calendario dell'offerta in opzione.
Capital/Financing Update Classification · 1% confidence The document is an official regulatory communication from BIOERA SPA, identified by the 'Informazione Regolamentata' header and filing details (Data/Ora Ricezione: 02 Marzo 2023). The subject ('Oggetto') explicitly states it is a 'Supplemento al prospetto informativo' (Supplement to the prospectus) and announces the extension of the option offer calendar ('Prorogato il calendario dell'offerta in opzione'). This document relates to a capital increase ('Aumento di Capitale in Opzione') and the associated prospectus, which is a core element of financing and capital structure activities. While it discusses a prospectus supplement, the primary action announced is the extension of the subscription period for a capital raise. This fits best under 'Capital/Financing Update' (CAP) as it directly concerns the terms and timeline of a capital increase offer, rather than being the full prospectus itself or a general regulatory announcement (RNS). It is not an Earnings Release (ER), Interim Report (IR), or a general AGM/Proxy document.
2023-03-02 Italian
BIOERA SPA Informativa al mercato ex. art. 114 tuf al 31 gennaio 2023
Regulatory Filings Classification · 1% confidence The document is titled "Informativa al mercato ai sensi dell'art. 114, comma 5, D.lgs. n. 58/98 ('TUF')" and reports financial data (Net Financial Indebtedness and overdue payables) as of January 31, 2023. This type of periodic disclosure, mandated by Article 114, paragraph 5 of the Italian Consolidated Financial Act (TUF) when requested by CONSOB (the Italian regulator), is a specific type of interim financial update that is more detailed than a standard Earnings Release (ER) but is not a full Annual Report (10-K) or a comprehensive Interim Report (IR). In the context of the provided definitions, this specific regulatory disclosure, which provides detailed financial metrics outside of the standard reporting cycle, most closely aligns with the requirements for an Interim / Quarterly Report (IR), as it provides a comprehensive look at key financial positions for a period shorter than a year (or a specific reporting date requested by the regulator). Since it is a detailed financial update for a specific point in time (31.01.2023) and not just an announcement of a report's publication, IR is the most appropriate classification.
2023-02-28 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.